Back to Search
Start Over
Tumor radiation therapy creates therapeutic vaccine responses to the colorectal cancer antigen GUCY2C.
- Source :
-
International journal of radiation oncology, biology, physics [Int J Radiat Oncol Biol Phys] 2014 Apr 01; Vol. 88 (5), pp. 1188-95. - Publication Year :
- 2014
-
Abstract
- Purpose: Radiation therapy (RT) is thought to produce clinical responses in cancer patients, not only through direct toxicity to cancer cells and supporting tumor stroma cells, but also through activation of immunologic effectors. More recently, RT has potentiated the local and systemic effects of cancer immunotherapy (IT). However, combination regimens that maximize immunologic and clinical efficacy remain undefined.<br />Methods and Materials: We evaluated the impact of local RT on adenoviral-mediated vaccination against the colorectal cancer antigen GUCY2C (Ad5-GUCY2C) in a murine subcutaneous tumor model using mouse CT26 colon cancer cells (CT26-GUCY2C). Immune responses were assessed by ELISpot, and clinical responses were assessed by tumor size and incidence.<br />Results: The specific sequence of tumor-directed RT preceding Ad5-GUCY2C IT transformed inactive therapeutic Ad5-GUCY2C vaccination into a curative vaccine. GUCY2C-specific T cell responses were amplified (P<.05), tumor eradication was maximized (P<.01), and tumor volumes were minimized (P<.001) in mice whose tumors were irradiated before, compared with after, Ad5-GUCY2C vaccination. The immunologic and antitumor efficacy of Ad5-GUCY2C was amplified comparably by unfractionated (8 Gy × 1), or biologically equivalent doses of fractionated (3.5 Gy × 3), RT. The antitumor effects of sequential RT and IT (RT-IT) depended on expression of GUCY2C by tumor cells and the adenoviral vaccine vector, and tumor volumes were inversely related to the magnitude of GUCY2C-specific T cell responses. Moreover, mice cured of CT26-GUCY2C tumors by RT-IT showed long-lasting antigen-dependent protection, resisting tumors formed by GUCY2C-expressing 4T1 breast cancer cells inoculated 50 days after CT26 cells.<br />Conclusions: Optimal sequencing of RT and IT amplifies antigen-specific local and systemic immune responses, revealing novel acute and long-term therapeutic antitumor protection. These observations underscore the importance of modality sequence optimization before the initiation of clinical trials of RT and IT to maximize immune and antitumor responses.<br /> (Copyright © 2014 Elsevier Inc. All rights reserved.)
- Subjects :
- Animals
Antigens, Neoplasm chemistry
Antineoplastic Agents chemistry
Cell Line, Tumor
Colorectal Neoplasms chemistry
Combined Modality Therapy methods
Disease Models, Animal
Enzyme-Linked Immunosorbent Assay
Epitopes chemistry
Humans
Mice
Mice, Inbred BALB C
Neoplasm Transplantation
Receptors, Enterotoxin
Time Factors
Treatment Outcome
Cancer Vaccines chemistry
Colorectal Neoplasms immunology
Colorectal Neoplasms radiotherapy
Immunotherapy methods
Receptors, Guanylate Cyclase-Coupled metabolism
Receptors, Peptide metabolism
Subjects
Details
- Language :
- English
- ISSN :
- 1879-355X
- Volume :
- 88
- Issue :
- 5
- Database :
- MEDLINE
- Journal :
- International journal of radiation oncology, biology, physics
- Publication Type :
- Academic Journal
- Accession number :
- 24661671
- Full Text :
- https://doi.org/10.1016/j.ijrobp.2013.12.043